Merck & Co.和Daichi Sankyo的癌症药物Patortumab deruxtecan在EGFR改型的NSCL病人的第三阶段试验中改善了无进展生存。 Merck & Co. and Daiichi Sankyo's cancer drug, patritumab deruxtecan, improved progression-free survival in a phase 3 trial for EGFR-mutated NSCLC patients.

默克公司和大井智康公司宣布,他们的癌症药物patritumab deruxtecan在EGFR突变非小细胞肺癌 (NSCLC) 患者的第3期试验中实现了其主要目标,这些患者之前接受过EGFR氨酸激酶抑制剂治疗. Merck & Co. and Daiichi Sankyo announced that their cancer drug, patritumab deruxtecan, achieved its primary goal in a phase 3 trial for patients with EGFR-mutated non-small cell lung cancer (NSCLC) previously treated with EGFR tyrosine kinase inhibitors. 与标准化疗相比,该药物在无病无病存活方面有了显著改善。 The drug showed a significant improvement in progression-free survival compared to standard chemotherapy. 虽然总体生存数据仍在评价中,但安全情况与以往研究相一致。 While overall survival data are still being evaluated, the safety profile aligned with prior studies.